Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2006

View Archived Issues

De Novo enters drug discovery collaboration with Genzyme

Potent and selective AEA reuptake inhibitors as antispastics in MS

A.P. Pharma sells royalty rights to Retin-A Micro and Carac

New investment supports GammaCan's phase II study of GCAN-101

BioVeris signs option agreement with TheraCarb for C. albicans vaccine candidate

Merck Frosst presents a new potent, selective orally active cathepsin K inhibitor

Phase I study completed for KB-2115

Department of Defense grant for preclinical study of Tarvacin for prostate cancer

Positive phase III results for SPP-100 in hypertension

Shareholders vote in favor of Crucell's offer for Berna

NanoCarrier to conduct phase I study of Nanoplatin in U.K.

Tolamba shows clinical benefit in reducing symptoms of ragweed allergy

GdSSR: A novel putative approach for glioblastoma multiforme treatment

NovImmune files IND for antibody for autoimmune disease

EDP-420 begins North American phase II trial for CAP

Enrollment nearing completion in phase IIIb mesothelioma study of Onconase

Phase III development of Acapodene recommended to continue

Panzem studied in phase II for recurring GBM

Arteriocyte studies adult derived hemangioblasts to treat chronic ischemia

Procyon Biopharma and Cellpep to merge to form Ambrilia Biopharma

HPV-specific inhibitors from Boehringer Ingelheim as a gateway for future drug design

Novel agents imparted for inflammatory disorders

Taisho patent describes compounds with potential for the treatment for renal disorders, etc.

Recent patents cover novel treatments for psychological disorders

Neuroprotective effects of targeting IKK for stroke

New therapeutics for cancer covered in recent patent literature

SuperGen withdraws Orathecin MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...